Success Metrics

Clinical Success Rate
100.0%

Based on 15 completed trials

Completion Rate
100%(15/15)
Active Trials
1(5%)
Results Posted
20%(3 trials)

Phase Distribution

Ph phase_3
5
25%
Ph phase_4
3
15%
Ph phase_1
1
5%
Ph not_applicable
5
25%
Ph phase_2
5
25%

Phase Distribution

1

Early Stage

5

Mid Stage

8

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
1(5.3%)
Phase 2Efficacy & side effects
5(26.3%)
Phase 3Large-scale testing
5(26.3%)
Phase 4Post-market surveillance
3(15.8%)
N/ANon-phased studies
5(26.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.8%

15 of 16 finished

Non-Completion Rate

6.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

20

all time

Status Distribution
Active(1)
Completed(15)
Terminated(1)
Other(3)

Detailed Status

Completed15
unknown3
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
20
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (5.3%)
Phase 25 (26.3%)
Phase 35 (26.3%)
Phase 43 (15.8%)
N/A5 (26.3%)

Trials by Status

completed1575%
withdrawn15%
recruiting15%
unknown315%

Recent Activity

Clinical Trials (20)

Showing 20 of 20 trials
NCT03640377Phase 2

Praziquantel in Children Under Age 4

Completed
NCT07074444Phase 4

Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel

Recruiting
NCT05354258Not Applicable

Feasibility and Safety of Combining Anti-malarial With Deworming Drugs in African Children

Unknown
NCT03779347Phase 3

Schistosomiasis Diagnosis Using a CAA Antigen Test

Unknown
NCT03893097Phase 3

Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children

Completed
NCT02734186Phase 4

Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis

Withdrawn
NCT01288872Phase 1

Praziquantel-Pharmacokinetic Study

Completed
NCT01154907

Prevention of Female Genital Schistosomiasis (FGS) in Rural High-endemic South Africa

Unknown
NCT02162875Not Applicable

Schistosoma Mansoni in Mwanza Region, Tanzania

Completed
NCT02878564Phase 4

Effect of Schistosomiasis Mansoni on HIV Susceptibility and Female Genital Immunology

Completed
NCT00486863Phase 2

S. Japonicum and Pregnancy Outcomes

Completed
NCT00441285Phase 2

Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ)

Completed
NCT00507221Not Applicable

Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression

Completed
NCT01901484Phase 2

Schistosoma Mansoni Morbidity in Children Aged 1-5 Years

Completed
NCT01722539Phase 3

Impact IPT With Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine in Schoolchildren

Completed
NCT01558336Phase 3

Schistosoma Haematobium Infections and Praziquantel

Completed
NCT01054651Phase 3

A Randomised Trial of Artesunate-sulfamethoxypyrazine/Pyrimethamine Versus Praziquantel for the Treatment of S. Mansoni

Completed
NCT00215267Not Applicable

The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda

Completed
NCT00510159Phase 2

Comparing Praziquantel Versus Artesunate + Sulfamethoxypyrazine/Pyrimethamine for Treating Schistosomiasis

Completed
NCT00231322Not Applicable

Influence of Transmission Season on Outcome of Treatment of Schistosoma Haematobium Infection in Mozambique

Completed

All 20 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
20